Leukemia and Lymphoma Program News

Your child will be cared for by one of the most accomplished teams of childhood cancer experts in the world. We provide medical care, emotional counseling and much more.

How we serve you

Existing patients or family members

215-590-3025

New patients, referrals and second opinions

267-426-0762

CHOP Researchers Win Science Center Award to Develop AML Treatment

Jan 27, 2020

The $200,000 award will fund research to develop a novel therapeutic that ignites the immune system and could act as a stand-alone treatment, as well as boost the effectiveness of existing immunotherapies.

AML Immunotherapy Trial Opens

Jan 23, 2020

CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.

Humanized CD19: CAR-T Immunotherapy for First Relapse of ALL in Down Syndrome Patient

Jan 11, 2019

An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.

Photograph of an acute lymphoblastic leukemia cell

CHOP Scientists Report How Some Cancer Cells Develop Resistance to CAR T-cell Therapy

Nov 27, 2018

CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.

No More Kids with Cancer Awards $220,000 to CHOP

Oct 5, 2018

The $220,000 award will be directed to a Phase I clinical trial that will investigate the effectiveness of CAR T-cell therapy to treat AML.

Advancing the Field of Cell Therapy

Sep 3, 2018

A bone marrow transplant saved Kaleo’s life. Today, he’s a dancing machine. His success story is an example of CHOP’s expertise in the field of cellular therapy.

Fellow’s Corner: An Excellent Teacher

Feb 5, 2018

Charles Phillips, MD, a CHOP fellow, recounts his experience caring for a cancer patient and the many firsts it brought to the both of them.

Hodgkin Lymphoma: Minimizing Late Effects, Long-term Risks

Feb 5, 2018

With the majority of Hodgkin lymphoma patients surviving their disease, the focus has turned to minimizing the long-term effects of treatment while maintaining excellent cure rates.

Shortened Inpatient Stays Benefit Certain Leukemia and Lymphoma Patients

Jul 25, 2018

Thanks to a recent initiative at CHOP, patients newly diagnosed with B-cell and T-cell ALL, and lymphoblastic lymphoma, now go home on average 9 days after diagnosis — that's 3 weeks sooner than previous stays.

Stand Up 2 Cancer Features Mitch Carbon's Immunotherapy Story

Sep 27, 2016

After four years of battling leukemia, Mitch was no longer responding to his cancer therapy. But new immunotherapy options at Children's Hospital gave him another chance to be a kid.

Find a research study

Innovation and your child

Find research studies